Abstracts Archive - Page 1192 of 2425 - ACR Meeting Abstracts

Abstract Number: 2813 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism with Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Trials
Rashmi Dhital¹, Dilli Poudel², Bidhya Timilsina³, Theresa Lynn³, Colin Peters³, Oreoluwa Oladiran³, Prem Parajuli³, Prakash Paudel⁴ and Anthony Donato³, ¹Reading Hospital-Tower Health System, West Reading, PA, ²Internal Medicine, Reading Hospital-Tower Health System, WEST READING, PA, ³Reading Hospital, West Reading, PA, ⁴Internal Medicine, Berkshire Medical Center, Pittsfield, MA
Background/Purpose: Selective Estrogen Receptor Modulators (SERMs) are one of the available treatment options for postmenopausal osteoporosis. Since Raloxifene was first introduced on 1997 for post-menopausal…
Abstract Number: 2814 • 2018 ACR/ARHP Annual Meeting
Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Fenglong Xie¹, Lang Chen¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) has been associated with reduced risk for cardiovascular disease (CVD) in several studies conducted among rheumatoid arthritis (RA) patients never exposed to…
Abstract Number: 2815 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Safety – Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials
Michael Weinblatt¹, Peter C. Taylor², Gerd R. Burmester³, Chadi Saifan⁴, Chad D. Walls⁴, Maher Issa⁴, Terence P. Rooney⁴ and Tsutomu Takeuchi⁵, ¹Brigham and Women’s Hospital, Boston, MA, ²Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ³Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Baricitinib (BARI), a selective inhibitor of Janus kinases, is approved in >40 countries for the treatment of active rheumatoid arthritis (RA) in adults. Patients…
Abstract Number: 2816 • 2018 ACR/ARHP Annual Meeting
Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis
Michelle J. Ormseth¹, Joseph F. Solus¹, Quanhu Sheng¹, Fei Ye¹, Yan Guo¹, Qiong Wu¹, Annette M. Oeser¹, Ryan Allen¹, Paolo Raggi², Kasey Vickers¹ and C Michael Stein¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Small noncoding RNAs (sRNAs), such as microRNAs (miRNAs), regulate gene expression and can be used as biomarkers of disease. Patients with rheumatoid arthritis (RA)…
Abstract Number: 2817 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro² and Kaleb Michaud^1,2, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Cardiovascular disease (CVD) represents the leading cause of death in RA, accounting for ~50% of excess mortality. Disease activity, strongly linked to CVD, has…
Abstract Number: 2818 • 2018 ACR/ARHP Annual Meeting
Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis
Panagiota Anyfanti¹, Eugenia Gkaliagkousi¹, Areti Triantafyllou¹, Eleni Gavriilaki¹, Panagiotis Dolgyras¹, Sophia Chatzimichailidou², Vasiliki Galanopoulou³, Stella Douma¹ and Spyros Aslanidis², ¹3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ²Rheumatology Department-2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ³Rheumatology Department, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece
Background/Purpose: Galectin-3 has emerged as a promising novel biomarker of cardiovascular fibrosis, that can improve cardiovascular risk stratification in high-risk populations. Rheumatoid arthritis (RA) is…
Abstract Number: 2819 • 2018 ACR/ARHP Annual Meeting
Alcohol Consumption and the Risk of Coronary Heart Disease and Mortality in Patients with Rheumatoid Arthritis
Isaac Smith¹, Jie Wei², Yuqing Zhang³, Hyon K. Choi² and Marcy Bolster¹, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of premature cardiovascular events and mortality. Prospective general population studies have shown moderate alcohol consumption…
Abstract Number: 2820 • 2018 ACR/ARHP Annual Meeting
Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
Yoshiya Tanaka¹, Koji Oba^2,3, Takao Koike^4,5, Nobuyuki Miyasaka⁶, Tsuneyo Mimori⁷, Tsutomu Takeuchi⁸, Shintaro Hirata⁹, Eiichi Tanaka¹⁰, Hidekata Yasuoka¹¹, Yuko Kaneko⁸, Kosaku Murakami⁷, Tomohiro Koga¹², Kazuhisa Nakano¹³, Koichi Amano¹⁴, Kazuyasu Ushio¹⁵, Tatsuya Atsumi¹⁶, Masayuki Inoo¹⁷, Kazuhiro Hatta¹⁸, Shinichi Mizuki¹⁹, Shohei Nagaoka²⁰, Shinichiro Tsunoda²¹, Hiroaki Dobashi²², Nao Horie³ and Norihiro Sato³, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, ³Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan, ⁴Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan, ⁵NTT Sapporo Medical Center, Sapporo, Japan, ⁶Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ¹⁰Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, ¹²Center for Bioinformatics and Molecular Medicine, Nagasaki University, Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁴Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹⁵Ushio Clinic, Osaka, Japan, ¹⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁷Utazu hospital, Utatsu-cho, Japan, ¹⁸Department of General Medicine, Tenri Hospital, Tenri, Japan, ¹⁹Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, ²⁰Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ²¹Division of Rheumatology Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²²Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Kagawa University, Miki-cho, Japan
Background/Purpose: Infliximab (IFX), a TNF inhibitor, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline levels of serum…
Abstract Number: 2821 • 2018 ACR/ARHP Annual Meeting
Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors
Cecilie Heegaard Brahe¹, Simon Krabbe¹, Mikkel Østergaard¹, Lykke Midtbøll Ørnbjerg¹, Daniel Glinatsi¹, Henrik Rogind¹, Hanne Slott Jensen², Annette Hansen³, Jesper Nørregaard⁴, Søren Jacobsen⁵, Lene Terslev¹, Tuan Khai Huynh⁴, Dorte Vendelbo Jensen⁶, Natalia Manilo², Karsten Asmussen², Per Brown-Frandsen⁵, Mikael Boesen⁷, Zoreh Rastiemadabadi⁷, Lone Morsel-Carlsen⁷, Jakob M. Møller⁸, Niels Steen Krogh⁹ and Merete Lund Hetland¹⁰, ¹Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ²Center for Rheumatology and Spine Diseases, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Denmark, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Nordsjællands Hospital, Hillerød, Denmark, Hillerød, Denmark, ⁵Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁶Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Copenhagen, Denmark, ⁷Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ⁸Department of Radiology, Copenhagen University Hospital Herlev, Copenhagen, Denmark, ⁹ZiteLab ApS, Copenhagen, Denmark, ¹⁰DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark
Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors Background/Purpose: A cohort of routine care…
Abstract Number: 2822 • 2018 ACR/ARHP Annual Meeting
Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
Guillaume Decarriere¹, Thomas Barnetche², Cédric Lukas³, Cécile Gaujoux-Viala⁴, Bernard Combe⁵, Jacques Morel⁶ and Claire I. Daien⁷, ¹Department of Rheumatology, CHU Lapeyronie, Montpellier, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), biologics are more efficient in combination with methotrexate (MTX) than in monotherapy. When MTX cannot be used, others csDMARD can…
Abstract Number: 2823 • 2018 ACR/ARHP Annual Meeting
Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
Daniela Santos Faria¹, Mónica Eusébio², Joana Leite Silva³, Joana Ramos Rodrigues¹, Joana Sousa Neves¹, Ana Catarina Duarte⁴, Carina Lopes⁵, Ana Valido⁶, Joana Dinis⁶, João Freitas⁷, Mariana Santiago⁷, Raquel Ferreira⁸, Sara Ganhão⁹, Luís Cunha Miranda¹⁰, Daniela Peixoto¹, Filipa Teixeira¹, Sérgio Alcino¹, Carmo Afonso¹, José Tavares Costa³ and Maria José Santos¹¹, ¹Rheumatology, ULSAM, Ponte de Lima, Portugal, ²Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, ³Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ⁴Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁵Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ⁶Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁷Rheumatology, Centro Hospitalar e Universitário de Coimbra, CHUC-EPE, Coimbra, Portugal, ⁸Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ⁹Rheumatology, Centro Hospitalar de São João, Porto, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Reuma.pt, Almada, Portugal, Almada, Portugal
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are highly effective treatments for active Rheumatoid Arthritis (RA). However, up to 40% of patients either fail to respond…
Abstract Number: 2824 • 2018 ACR/ARHP Annual Meeting
On Tapering Therapy for RA Patients in Clinical Remission; Flare on Csdmards Predicted By Clinical Features and Musculoskeletal Ultrasound, Whereas T-Cell Abnormalities Predictive for b-DMARD Tapering
Hanna Gul¹, Frederique Ponchel² and Paul Emery³, ¹Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Tapering of disease-modifying therapy (DMARDs) is recommended by EULAR/ACR for rheumatoid arthritis (RA) patients who achieve sustained remission on stable therapy. However, there is…
Abstract Number: 2825 • 2018 ACR/ARHP Annual Meeting
Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab
Ana Martínez^1,2, Chamaida Plasencia^2,3, Victoria Navarro-Compán², Borja Hernández-Breijo², Dora Pascual-Salcedo², Pilar Nozal⁴, Cristina Diego⁴, Irene Monjo^2,3, Laura Nuño^3,5 and Alejandro Balsa^2,6, ¹Immunology. La Paz University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴La Paz University Hospital, Immunology, Madrid, Spain, ⁵Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Rituximab (Rtx) induces transient depletion of B cells. Previous data showed that Rtx is particularly effective on autoimmune diseases in which auto-antibodies (auto-Ab) are…
Abstract Number: 2826 • 2018 ACR/ARHP Annual Meeting
Emergence of Severe Spondyloarthropathy Related Entheseal Pathology Following Successful Vedolizumab Therapy for Inflammatory Bowel Disease
Sayam Dubash^1,2, Marianayagam Thiraupathy³, Ilaria Tinazzi⁴, Tariq Al Araimi⁵, Christian Pagnoux⁶, Adam Weizman⁷, Pascal Richette^8,9, My-Linh Tran Minh¹⁰, Mattieu Allez¹⁰, Animesh Singh¹¹, Francesco Ciccia¹², John Hamlin¹³, Ai Lyn Tan^1,2, Helena Marzo-Ortega^1,2 and Dennis McGonagle^1,2, ¹Rheumatology, Chapel Allerton Hospital, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³East and North Hertfordshire NHS Trust, Stevenage, United Kingdom, ⁴Rheumatology, Sacro Cuore-Don Calabria Hospital, Negrar, Italy, ⁵Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁷Gastroenterology, Mount Sinai Hospital, Toronto, ON, Canada, ⁸Rheumatology, Université Paris Diderot, Paris, France, ⁹Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ¹⁰Department of Gastroenterology, APHP, Hôpital Saint Louis, Sorbonne Paris-Cité University, Paris, France, ¹¹Rheumatology, The Royal Free Hospital, London, United Kingdom, ¹²Rheumatology, University of Palermo, Palermo, Italy, ¹³Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Vedolizumab therapy for inflammatory bowel disease (IBD) has been associated with mild spondyloarthritis (SpA) related features including sacroiliitis and synovitis. Herein, we report a…
Abstract Number: 2827 • 2018 ACR/ARHP Annual Meeting
Remission Targets and Prevention of Subclinical Atherosclerosis in Psoriatic Arthritis- Which Target Should We Choose?
Isaac T. Cheng¹, Qing Shang², Edmund Kwok Ming Li², Priscilla Wong¹, Lydia Ho Pui Tam², Tracy Y. Zhu³, M Mimi Chang⁴, JW Jack LEE⁵, PW Alex Lee² and Lai-Shan Tam⁴, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Bone Quality and Health Centre of the Department of Orthopedics & Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ⁴Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵Biostatistics Division, School of Public and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Systemic inflammation contributes to the excess risk of cardiovascular disease (CVD) in PsA. We had demonstrated that achieving sustained minimal disease activity (sMDA) was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].